Zentalis Pharmaceuticals, Inc. ZNTL
We take great care to ensure that the data presented and summarized in this overview for Zentalis Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZNTL
View all-
Matrix Capital Management Company, LP Waltham, MA14MShares$44.4 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$27.2 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$15.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$14.7 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$9.88 Million2.71% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.72MShares$8.64 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC2.1MShares$6.68 Million23.31% of portfolio
-
Morgan Stanley New York, NY1.61MShares$5.12 Million0.0% of portfolio
-
Verition Fund Management LLC Greenwich, CT1.5MShares$4.78 Million0.03% of portfolio
-
Primecap Management CO Pasadena, CA1.5MShares$4.76 Million0.0% of portfolio
Latest Institutional Activity in ZNTL
Top Purchases
Top Sells
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Insider Transactions at ZNTL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 13
2024
|
Scott Dunseth Myers Director |
BUY
Grant, award, or other acquisition
|
Direct |
260,192
+50.0%
|
-
|
Oct 04
2024
|
Vincent Vultaggio Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,603
-4.52%
|
$4,809
$3.18 P/Share
|
Jun 21
2024
|
Enoch Kariuki Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,581
+34.27%
|
-
|
Jun 21
2024
|
Jan Skvarka Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,581
+31.71%
|
-
|
Jun 21
2024
|
David Michael Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,429
+20.07%
|
-
|
May 31
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
9,597
-1.49%
|
$105,567
$11.98 P/Share
|
May 24
2024
|
Luke Nathaniel Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,481
+50.0%
|
-
|
May 09
2024
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,356
-0.89%
|
$40,272
$12.62 P/Share
|
Feb 12
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
1,173
-0.18%
|
$12,903
$11.44 P/Share
|
Feb 12
2024
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,573
-0.57%
|
$28,303
$11.44 P/Share
|
Feb 02
2024
|
Andrea Paul Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,310
-2.16%
|
$36,410
$11.54 P/Share
|
Feb 02
2024
|
Mark Lackner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,585
-0.8%
|
$17,435
$11.54 P/Share
|
Feb 02
2024
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,669
-1.87%
|
$95,359
$11.54 P/Share
|
Feb 02
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
11,552
-1.76%
|
$127,072
$11.54 P/Share
|
Feb 01
2024
|
Andrea Paul Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+42.33%
|
-
|
Feb 01
2024
|
Mark Lackner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,000
+41.68%
|
-
|
Feb 01
2024
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
337,500
+47.22%
|
-
|
Feb 01
2024
|
Kimberly Blackwell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,655
-4.09%
|
$227,205
$11.69 P/Share
|
Feb 01
2024
|
Kimberly Blackwell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+33.12%
|
-
|
Feb 01
2024
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+13.95%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.61M shares |
---|
Open market or private sale | 43.4K shares |
---|---|
Payment of exercise price or tax liability | 20.7K shares |